172 related articles for article (PubMed ID: 34413629)
1. HHLA2 Expression is Associated with Poor Survival in Patients with Hepatocellular Carcinoma.
Xu Y; Huang Z; Yu X; Li Z; Zheng L; Xu J
Biologics; 2021; 15():329-341. PubMed ID: 34413629
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment.
Luo M; Lin Y; Liang R; Li Y; Ge L
J Inflamm Res; 2021; 14():4217-4228. PubMed ID: 34483677
[TBL] [Abstract][Full Text] [Related]
3. Interferon Gamma-Induced Interferon Regulatory Factor 1 Activates Transcription of HHLA2 and Induces Immune Escape of Hepatocellular Carcinoma Cells.
Wang R; Guo H; Tang X; Zhang T; Liu Y; Zhang C; Yu H; Li Y
Inflammation; 2022 Feb; 45(1):308-330. PubMed ID: 34536158
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma.
Ding L; Yu Q; Yang S; Yang WJ; Liu T; Xian JR; Tian TT; Li T; Chen W; Wang BL; Pan BS; Zhou J; Fan J; Yang XR; Guo W
Front Immunol; 2022; 13():831101. PubMed ID: 35371079
[TBL] [Abstract][Full Text] [Related]
5. H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro.
Luo M; Xiong Y; Lin Y; Liang R; Li Y; Ge L
Med Sci Monit; 2021 May; 27():e930215. PubMed ID: 33990536
[TBL] [Abstract][Full Text] [Related]
6. HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma.
Liao X; Zhang D
Am J Clin Pathol; 2022 Jul; 158(1):62-69. PubMed ID: 35084443
[TBL] [Abstract][Full Text] [Related]
7. Prognostic values of B7-H3, B7-H4, and HHLA2 expression in human pancreatic cancer tissues based on mIHC and spatial distribution analysis.
Zhu Y; Chen J; Liu Y; Zheng X; Feng J; Chen X; Jiang T; Li Y; Chen L
Pathol Res Pract; 2022 Jun; 234():153911. PubMed ID: 35489125
[TBL] [Abstract][Full Text] [Related]
8. HHLA2 immune-regulatory roles in cancer.
Mortezaee K
Biomed Pharmacother; 2023 Jun; 162():114639. PubMed ID: 37011487
[TBL] [Abstract][Full Text] [Related]
9. HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.
Huang FX; Wu JW; Cheng XQ; Wang JH; Wen XZ; Li JJ; Zhang Q; Jiang H; Ding QY; Zhu XF; Zhang XS; Ding Y; Li DD
Front Immunol; 2022; 13():902167. PubMed ID: 36003385
[TBL] [Abstract][Full Text] [Related]
10. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma.
Zhou QH; Li KW; Chen X; He HX; Peng SM; Peng SR; Wang Q; Li ZA; Tao YR; Cai WL; Liu RY; Huang H
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959726
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 is Upregulated and Independently Predicts Unfavorable Prognosis in Bladder Urothelial Carcinoma.
Lin G; Ye H; Wang J; Chen S; Chen X; Zhang C
Nephron; 2019; 141(4):256-264. PubMed ID: 30602154
[TBL] [Abstract][Full Text] [Related]
12. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
[TBL] [Abstract][Full Text] [Related]
13. High expression of HHLA2 predicts poor prognosis in medullary thyroid carcinoma.
Niu Y; Wang W; Jiang X; Huang Y; Yan S; Jiang Y
Jpn J Clin Oncol; 2022 Jul; 52(7):759-765. PubMed ID: 35348687
[TBL] [Abstract][Full Text] [Related]
14. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
15. B7 score and T cell infiltration stratify immune status in prostate cancer.
Zhou Q; Li K; Lai Y; Yao K; Wang Q; Zhan X; Peng S; Cai W; Yao W; Zang X; Xu K; Huang J; Huang H
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34417325
[TBL] [Abstract][Full Text] [Related]
16. Human Endogenous Retrovirus-H Long Terminal Repeat- Associating Protein 2 (HHLA2) is a Novel Immune Checkpoint Protein in Lung Cancer which Predicts Survival.
Farrag MS; Ibrahim EM; El-Hadidy TA; Akl MF; Elsergany AR; Abdelwahab HW
Asian Pac J Cancer Prev; 2021 Jun; 22(6):1883-1889. PubMed ID: 34181347
[TBL] [Abstract][Full Text] [Related]
17. HHLA2 promotes hepatoma cell proliferation, migration, and invasion via SPP1/PI3K/AKT signaling pathway.
Wang J; Yang K; Yang X; Jin T; Tian Y; Dai C; Xu F
Mol Carcinog; 2024 Jul; 63(7):1275-1287. PubMed ID: 38578157
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological suppression of HHLA2 glycosylation restores anti-tumor immunity in colorectal cancer.
Zhang D; Xie J; Sun F; Xu R; Liu W; Xu J; Huang X; Zhang G
Cancer Lett; 2024 May; 589():216819. PubMed ID: 38522775
[TBL] [Abstract][Full Text] [Related]
19. Clinical Value of Human Endogenous Retrovirus-H Long Terminal Repeat Associating 2 (HHLA2) in Small Cell Lung Cancer.
Zhang X; Qin Y; Chen X; Xiong M; Shu S
Technol Cancer Res Treat; 2024; 23():15330338241240683. PubMed ID: 38613340
[No Abstract] [Full Text] [Related]
20. Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients.
Chen L; Zhu D; Feng J; Zhou Y; Wang Q; Feng H; Zhang J; Jiang J
Cancer Cell Int; 2019; 19():101. PubMed ID: 31015801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]